140 related articles for article (PubMed ID: 37964487)
1. De novo variants in KCNA3 cause developmental and epileptic encephalopathy.
Soldovieri MV; Ambrosino P; Mosca I; Servettini I; Pietrunti F; Belperio G; ; Syrbe S; Taglialatela M; Lemke JR
Ann Neurol; 2024 Feb; 95(2):365-376. PubMed ID: 37964487
[TBL] [Abstract][Full Text] [Related]
2. Distinct epilepsy phenotypes and response to drugs in KCNA1 gain- and loss-of function variants.
Miceli F; Guerrini R; Nappi M; Soldovieri MV; Cellini E; Gurnett CA; Parmeggiani L; Mei D; Taglialatela M
Epilepsia; 2022 Jan; 63(1):e7-e14. PubMed ID: 34778950
[TBL] [Abstract][Full Text] [Related]
3. De novo FZR1 loss-of-function variants cause developmental and epileptic encephalopathies.
Manivannan SN; Roovers J; Smal N; Myers CT; Turkdogan D; Roelens F; Kanca O; Chung HL; Scholz T; Hermann K; Bierhals T; Caglayan HS; Stamberger H; ; Mefford H; de Jonghe P; Yamamoto S; Weckhuysen S; Bellen HJ
Brain; 2022 Jun; 145(5):1684-1697. PubMed ID: 34788397
[TBL] [Abstract][Full Text] [Related]
4. A Novel
Imbrici P; Conte E; Blunck R; Stregapede F; Liantonio A; Tosi M; D'Adamo MC; De Luca A; Brankovic V; Zanni G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576077
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Functional Study of a De Novo Variant in the PVP Motif of Kv1.1 Channel Associated with Epilepsy, Developmental Delay and Ataxia.
Dinoi G; Morin M; Conte E; Mor Shaked H; Coppola MA; D'Adamo MC; Elpeleg O; Liantonio A; Hartmann I; De Luca A; Blunck R; Russo A; Imbrici P
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897654
[TBL] [Abstract][Full Text] [Related]
6. A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetine.
Ambrosino P; Ragona F; Mosca I; Vannicola C; Canafoglia L; Solazzi R; Rivolta I; Freri E; Granata T; Messina G; Castellotti B; Gellera C; Soldovieri MV; DiFrancesco JC; Taglialatela M
Epilepsia; 2023 Jul; 64(7):e148-e155. PubMed ID: 37203213
[TBL] [Abstract][Full Text] [Related]
7. Human
Wei AD; Wakenight P; Zwingman TA; Bard AM; Sahai N; Willemsen MH; Schelhaas HJ; Stegmann APA; Verhoeven JS; de Man SA; Wessels MW; Kleefstra T; Shinde DN; Helbig KL; Basinger A; Wagner VF; Rodriguez-Buritica D; Bryant E; Millichap JJ; Millen KJ; Dobyns WB; Ramirez JM; Kalume FK
J Neurophysiol; 2022 Jul; 128(1):40-61. PubMed ID: 35583973
[TBL] [Abstract][Full Text] [Related]
8. Tracking the motion of the K
Pantazis A; Kaneko M; Angelini M; Steccanella F; Westerlund AM; Lindström SH; Nilsson M; Delemotte L; Saitta SC; Olcese R
J Physiol; 2020 Nov; 598(22):5245-5269. PubMed ID: 32833227
[TBL] [Abstract][Full Text] [Related]
9. Loss-of-function variants in the KCNQ5 gene are implicated in genetic generalized epilepsies.
Krüger J; Schubert J; Kegele J; Labalme A; Mao M; Heighway J; Seebohm G; Yan P; Koko M; Aslan-Kara K; Caglayan H; Steinhoff BJ; Weber YG; Keo-Kosal P; Berkovic SF; Hildebrand MS; Petrou S; Krause R; May P; Lesca G; Maljevic S; Lerche H
EBioMedicine; 2022 Oct; 84():104244. PubMed ID: 36088682
[TBL] [Abstract][Full Text] [Related]
10. Expanding the genotype-phenotype correlation of de novo heterozygous missense variants in YWHAG as a cause of developmental and epileptic encephalopathy.
Kanani F; Titheradge H; Cooper N; Elmslie F; Lees MM; Juusola J; Pisani L; McKenna C; Mignot C; Valence S; Keren B; Lachlan K; ; Balasubramanian M
Am J Med Genet A; 2020 Apr; 182(4):713-720. PubMed ID: 31926053
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional assessment of two novel KCNQ2 gain-of-function variants Y141N and G239S and effects of amitriptyline treatment.
Bayat A; Iavarone S; Miceli F; Jakobsen AV; Johannesen KM; Nikanorova M; Ploski R; Szymanska K; Flamini R; Cooper EC; Weckhuysen S; Taglialatela M; Møller RS
Neurotherapeutics; 2024 Jan; 21(1):e00296. PubMed ID: 38241158
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum and genotype-phenotype associations of KCNA2-related encephalopathies.
Masnada S; Hedrich UBS; Gardella E; Schubert J; Kaiwar C; Klee EW; Lanpher BC; Gavrilova RH; Synofzik M; Bast T; Gorman K; King MD; Allen NM; Conroy J; Ben Zeev B; Tzadok M; Korff C; Dubois F; Ramsey K; Narayanan V; Serratosa JM; Giraldez BG; Helbig I; Marsh E; O'Brien M; Bergqvist CA; Binelli A; Porter B; Zaeyen E; Horovitz DD; Wolff M; Marjanovic D; Caglayan HS; Arslan M; Pena SDJ; Sisodiya SM; Balestrini S; Syrbe S; Veggiotti P; Lemke JR; Møller RS; Lerche H; Rubboli G
Brain; 2017 Sep; 140(9):2337-2354. PubMed ID: 29050392
[TBL] [Abstract][Full Text] [Related]
13. De novo KCNB1 mutations in epileptic encephalopathy.
Torkamani A; Bersell K; Jorge BS; Bjork RL; Friedman JR; Bloss CS; Cohen J; Gupta S; Naidu S; Vanoye CG; George AL; Kearney JA
Ann Neurol; 2014 Oct; 76(4):529-540. PubMed ID: 25164438
[TBL] [Abstract][Full Text] [Related]
14. A novel epileptic encephalopathy mutation in KCNB1 disrupts Kv2.1 ion selectivity, expression, and localization.
Thiffault I; Speca DJ; Austin DC; Cobb MM; Eum KS; Safina NP; Grote L; Farrow EG; Miller N; Soden S; Kingsmore SF; Trimmer JS; Saunders CJ; Sack JT
J Gen Physiol; 2015 Nov; 146(5):399-410. PubMed ID: 26503721
[TBL] [Abstract][Full Text] [Related]
15. KCNA1 gain-of-function epileptic encephalopathy treated with 4-aminopyridine.
Müller P; Takacs DS; Hedrich UBS; Coorg R; Masters L; Glinton KE; Dai H; Cokley JA; Riviello JJ; Lerche H; Cooper EC
Ann Clin Transl Neurol; 2023 Apr; 10(4):656-663. PubMed ID: 36793218
[TBL] [Abstract][Full Text] [Related]
16. De novo KCNA1 variants in the PVP motif cause infantile epileptic encephalopathy and cognitive impairment similar to recurrent KCNA2 variants.
Rogers A; Golumbek P; Cellini E; Doccini V; Guerrini R; Wallgren-Pettersson C; Thuresson AC; Gurnett CA
Am J Med Genet A; 2018 Aug; 176(8):1748-1752. PubMed ID: 30055040
[TBL] [Abstract][Full Text] [Related]
17. Gain of function due to increased opening probability by two
Nappi M; Barrese V; Carotenuto L; Lesca G; Labalme A; Ville D; Smol T; Rama M; Dieux-Coeslier A; Rivier-Ringenbach C; Soldovieri MV; Ambrosino P; Mosca I; Pusch M; Miceli F; Taglialatela M
Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2116887119. PubMed ID: 35377796
[TBL] [Abstract][Full Text] [Related]
18. De Novo Missense Variants in SLC32A1 Cause a Developmental and Epileptic Encephalopathy Due to Impaired GABAergic Neurotransmission.
Platzer K; Sticht H; Bupp C; Ganapathi M; Pereira EM; Le Guyader G; Bilan F; Henderson LB; Lemke JR; Taschenberger H; Brose N; Abou Jamra R; Wojcik SM
Ann Neurol; 2022 Dec; 92(6):958-973. PubMed ID: 36073542
[TBL] [Abstract][Full Text] [Related]
19. Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy.
Corbett MA; Bellows ST; Li M; Carroll R; Micallef S; Carvill GL; Myers CT; Howell KB; Maljevic S; Lerche H; Gazina EV; Mefford HC; Bahlo M; Berkovic SF; Petrou S; Scheffer IE; Gecz J
Neurology; 2016 Nov; 87(19):1975-1984. PubMed ID: 27733563
[TBL] [Abstract][Full Text] [Related]
20. A Recurrent De Novo PACS2 Heterozygous Missense Variant Causes Neonatal-Onset Developmental Epileptic Encephalopathy, Facial Dysmorphism, and Cerebellar Dysgenesis.
Olson HE; Jean-Marçais N; Yang E; Heron D; Tatton-Brown K; van der Zwaag PA; Bijlsma EK; Krock BL; Backer E; Kamsteeg EJ; Sinnema M; Reijnders MRF; Bearden D; Begtrup A; Telegrafi A; Lunsing RJ; Burglen L; Lesca G; Cho MT; Smith LA; Sheidley BR; Moufawad El Achkar C; Pearl PL; Poduri A; Skraban CM; Tarpinian J; Nesbitt AI; Fransen van de Putte DE; Ruivenkamp CAL; Rump P; Chatron N; Sabatier I; De Bellescize J; Guibaud L; Sweetser DA; Waxler JL; Wierenga KJ; ; Donadieu J; Narayanan V; Ramsey KM; ; Nava C; Rivière JB; Vitobello A; Tran Mau-Them F; Philippe C; Bruel AL; Duffourd Y; Thomas L; Lelieveld SH; Schuurs-Hoeijmakers J; Brunner HG; Keren B; Thevenon J; Faivre L; Thomas G; Thauvin-Robinet C
Am J Hum Genet; 2018 May; 102(5):995-1007. PubMed ID: 29656858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
